Mounjaro is a brand name for tirzepatide, a once-weekly injectable medication that activates two gut hormone receptors — GIP and GLP-1 — rather than the single GLP-1 receptor targeted by older medications in this class. According to the FDA label, Mounjaro is approved as an adjunct to diet and exercise to improve blood sugar control in people with type 2 diabetes, and, as of an FDA action in August 2026, to reduce the risk of cardiovascular death, nonfatal heart attack, and nonfatal stroke in adults with type 2 diabetes who are at high risk for those events.
It is worth being precise about something patients are rarely told clearly: Mounjaro itself is not FDA-approved for weight loss. Tirzepatide is also sold under the brand name Zepbound, and it is Zepbound that carries FDA approval for chronic weight management in adults with obesity, or overweight with a weight-related condition, and — since December 2024 — for moderate-to-severe obstructive sleep apnea in adults with obesity. Same active ingredient, two labels, two sets of approved uses. There is no FDA-approved generic tirzepatide, and compounded tirzepatide is not an FDA-approved product.
At Atlanta Medical Institute, our Buckhead physicians treat that distinction as a clinical decision rather than a marketing one. Whether tirzepatide is appropriate for you at all, which product fits your diagnosis and coverage, and what dose you take are determined by a physician after a full evaluation of your medical history, current medications, labs, and goals. Some patients who come in asking for Mounjaro by name turn out to be better served by a different medication, or by addressing a thyroid, hormone, or metabolic issue first.
We have practiced at one location on Roswell Road since 2010, and the physician who starts your program is the physician who follows it. That continuity matters with a medication that is titrated slowly over months and monitored the whole way.
Program Benefits
- A full physician evaluation before any prescription is written, including review of your medical history, medication list, and relevant labs
- Individualized dose titration supervised by a physician rather than a fixed protocol
- Ongoing monitoring of weight, blood pressure, blood sugar, and side effects at scheduled follow-up visits
- Nutrition and lifestyle coaching alongside the medication, since the evidence supports the two together
- Honest guidance on FDA-approved products versus compounded alternatives, and what that difference means for you
- Coordination with our hormone, thyroid, and metabolic services when another condition is contributing to weight gain
How Tirzepatide Works
Tirzepatide is a single molecule that acts on two incretin receptors. GLP-1 receptor activation slows gastric emptying, increases satiety, and stimulates insulin release when blood sugar is elevated. GIP receptor activation appears to add further effects on appetite regulation and on how the body handles fat and glucose. The practical result most patients notice first is that hunger quiets down and meals end sooner.
It is given as a subcutaneous injection once a week, and treatment starts at a low dose that is increased gradually. The purpose of that slow start is tolerability: most of the gastrointestinal side effects associated with this drug class are worst in the weeks immediately after a dose increase. Your physician sets and adjusts your dose — we do not publish dosing schedules, because the right schedule depends on how you personally respond.
What the Evidence Actually Shows
The largest published obesity trial of tirzepatide, SURMOUNT-1, was published in the New England Journal of Medicine in 2022. Over 72 weeks, adults with obesity or overweight who did not have diabetes lost an average of roughly 15 to 21 percent of their body weight depending on dose, compared with about 3 percent in the placebo group. That trial supported the Zepbound approval. These are group averages from a controlled trial with structured diet and activity support built in; they are not a prediction of what any individual will experience, and a meaningful number of participants lost considerably less.
SURMOUNT-4, published in JAMA, addressed a question patients ask constantly: what happens if you stop? After 36 weeks of open-label tirzepatide, participants who were switched to placebo regained weight over the following year, while those who continued the medication lost somewhat more. The honest reading is that tirzepatide is treatment for an ongoing condition, not a course you finish. Stopping is a decision to make with your physician, with a plan attached.
On the cardiovascular side, the SURPASS-CVOT trial compared tirzepatide head-to-head against dulaglutide in more than 13,000 adults with type 2 diabetes and established cardiovascular disease, and supported the 2026 FDA indication for reducing major adverse cardiovascular events. We cite these studies by name so you can look them up, and we would rather tell you what is uncertain than overstate what is known.
Who Is a Candidate
Candidacy is a medical judgment made after an in-person evaluation, not something you can determine from a website or a quiz. Broadly, our physicians consider your diagnosis, body mass index, weight-related conditions such as high blood pressure, sleep apnea, fatty liver, or prediabetes, what you have already tried, and your full medication list.
Per the FDA label, tirzepatide is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and in anyone with a known serious hypersensitivity to the drug. It is not recommended in people with severe gastroparesis. Your physician will also weigh a history of pancreatitis, gallbladder disease, diabetic retinopathy, kidney disease, eating disorders, pregnancy or plans to become pregnant, and use of insulin or other diabetes medications that can cause low blood sugar.
- Bring a complete list of medications and supplements, including doses
- Tell us about any personal or family history of thyroid cancer or endocrine tumors
- Tell us about prior pancreatitis, gallbladder problems, or significant GI disease
- Tell us if you are pregnant, breastfeeding, or planning pregnancy
- Tell any surgeon or anesthesiologist that you take this medication before a procedure
What to Expect in the Program
Your first visit is a consultation and workup: history, physical, and the labs your physician thinks are warranted. If tirzepatide is appropriate, you will leave with a plan that covers how the medication is obtained, how it is stored and injected, what side effects to expect early on, and when to call us.
Follow-up is frequent at the start and spaces out as your dose stabilizes. At each visit we review weight, blood pressure, symptoms, and labs where indicated, and adjust. Patients who pair the medication with protein-forward eating, resistance training, and adequate hydration generally tolerate it better and hold their results more durably — which is why nutrition coaching is part of the program rather than an upsell.
Safety, Side Effects, and Monitoring
Mounjaro carries a boxed warning: tirzepatide caused thyroid C-cell tumors in rats, and it is not known whether it causes such tumors, including medullary thyroid carcinoma, in humans. This is why the contraindications above are absolute rather than advisory.
The most common side effects listed on the label, each occurring in at least 5 percent of patients, are nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, and abdominal pain. These are usually worst after a dose increase and often ease with time, slower titration, smaller meals, and attention to hydration. The label also carries warnings for acute pancreatitis, gallbladder disease, acute kidney injury related to dehydration from vomiting or diarrhea, severe gastrointestinal reactions, worsening of diabetic retinopathy, low blood sugar when combined with insulin or insulin secretagogues, serious hypersensitivity reactions, and the risk of pulmonary aspiration during anesthesia because the stomach may empty more slowly than expected.
Call the office if you develop severe or persistent abdominal pain, cannot keep fluids down, or notice vision changes. Seek emergency care for signs of a severe allergic reaction. We would rather hear from you early than manage a complication late.
How This Fits with Our Other Services
The Mounjaro program sits inside our broader medical weight loss practice. If a different agent is a better fit, we also run tirzepatide, semaglutide, Ozempic, Wegovy, and general obesity treatment programs, and your physician will explain the trade-offs among them rather than defaulting to whichever brand is most recognized.
Weight is rarely a standalone problem. Our physicians — Dr. Elbridge Bills and Dr. Leslye Pace, our chief medical officer — also treat hormone imbalance, menopause symptoms, low testosterone, and age-related metabolic change, and it is common for a weight plan to run alongside hormone or thyroid evaluation. Everything happens at our single Buckhead office at 5009 Roswell Road NE, Suite 201. To ask whether tirzepatide makes sense for you, call (404) 264-9553 or use the contact page to request a consultation.
Patient Reviews
"Down 52 lbs in 6 months. The Mounjaro protocol completely changed my relationship with food."
Related Patient Videos
Frequently Asked Questions
Is Mounjaro approved by the FDA for weight loss?+
No. Mounjaro's FDA-approved uses are improving blood sugar control in type 2 diabetes and, as of August 2026, reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes at high cardiovascular risk. Zepbound is the tirzepatide brand that is FDA-approved for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity. Prescribing a medication outside its labeled indication is legal and sometimes appropriate, but you deserve to know when that is what is happening.
What is the difference between Mounjaro, Zepbound, and tirzepatide?+
Tirzepatide is the active ingredient. Mounjaro and Zepbound are two brand names for that same ingredient from the same manufacturer, approved for different uses and supplied in different pens. There is no FDA-approved generic tirzepatide on the market.
Is compounded tirzepatide the same thing, and is it cheaper?+
Compounded tirzepatide is not an FDA-approved product, and it is not reviewed by the FDA for safety, effectiveness, or quality. After the tirzepatide shortage was resolved, the FDA ended its enforcement discretion for compounding tirzepatide in 2025, and in 2026 proposed permanently excluding it from the list of bulk substances that outsourcing facilities may use. The FDA has also reported adverse events tied to dosing errors with compounded versions. We will discuss cost openly with you, but we are not going to pretend an unapproved product is equivalent.
How much weight will I lose?+
We cannot tell you that, and you should be skeptical of anyone who does. Published trial averages range widely by dose and population, and individual response varies a great deal. Some patients respond strongly, some modestly, and some not enough to justify continuing. Your physician will set a review point to assess whether the medication is doing enough to be worth staying on.
What happens if I stop taking it?+
In the SURMOUNT-4 trial, participants who stopped tirzepatide regained weight over the following year, while those who continued maintained or improved on their results. Obesity and type 2 diabetes are chronic conditions, and this medication treats them rather than resolving them. If you want to come off it, we build a plan for that rather than having you stop abruptly on your own.
Will my insurance cover it?+
Coverage varies enormously by plan and by indication, and it changes year to year. Coverage is often easier to obtain for a diabetes diagnosis than for weight management. Our staff will tell you what we know about your specific plan, but we cannot promise coverage or a particular price.
Do I need to tell my other doctors I am taking this?+
Yes. Tell every clinician who treats you, and make a point of telling any surgeon, gastroenterologist, or anesthesiologist before a procedure or endoscopy, because the medication can slow stomach emptying and the FDA label warns about the risk of aspiration under anesthesia. Also tell us about every medication you take, since tirzepatide can affect how other drugs are absorbed and can cause low blood sugar when combined with insulin or certain diabetes medications.
Costs and appointment planning
Review pricing questions, insurance and coverage information, and telehealth visit planning before booking. Confirm the costs and services that apply to your individual care.
Ready to Get Started?
Call us at (404) 264-9553 or book a telehealth consultation. New patients qualify for our 1st month Semaglutide special — $399 (regularly $450).